Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25487589 | 0.86 | PLA2G2A (0.49) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL25487575 | 0.84 | ALDH1A1 (0.51) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL16131036 | 0.75 | KMT2A (0.56) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL21986694 | 0.73 | MEN1 (0.41) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL2372967 | 0.73 | NPSR1 (0.52) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL1648076 | 0.72 | NCEH1 (0.59) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL22644832 | 0.72 | MEN1 (0.49) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL5963018 | 0.72 | CYP3A4 (0.47) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL38662586 | 0.72 | MEN1 (0.71) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL2443270 | 0.72 | MEN1 (0.71) | KMT2AMEN1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | CELGENE CAR LLC (BM) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | WEE2, WEE1, CDK2 | KMT2A 168/4885MEN1 1195/4885ALDH1A1 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.